Participants 62 151 6
patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin
Participants 462 562 5
treatment-naive patients with HCV genotype 1 infection enrolled in a large expanded access programme
Participants 572 609 9
Eight hundred and ninety-one patients
